Akari Therapeutics, Plc (AKTX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 London, 영국. 현재 CEO는 Abizer Gaslightwala.
AKTX 을(를) 보유 IPO 날짜 2014-01-06, 8 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $4.26M.
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
